We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

73 hedge funds and large institutions have $205M invested in AEON Biopharma in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

3% more funds holding

Funds holding: 71 → 73 (+2)

1% more capital invested

Capital invested by funds: $202M → $205M (+$2.65M)

0.05% more ownership

Funds ownership: 1.04% → 1.09% (+0.05%)

Holders
73
Holders Change
+2
Holders Change %
+2.82%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
6
Closed
6
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$5.51M
2
UOC
UBS O'Connor
Illinois
+$5.13M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$2.91M
4
FTCM
First Trust Capital Management
Illinois
+$2.45M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
-$5.51M
2
Citadel Advisors
Citadel Advisors
Florida
-$4.89M
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.22M
4
JP Morgan Chase
JP Morgan Chase
New York
-$1.01M
5
AR
Advisory Research
Illinois
-$991K
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
AQR Arbitrage
Connecticut
$2.62M +$1.61M +2,281 +160%
CCA
27
Castle Creek Arbitrage
Colorado
$2.5M – – –
FTCM
28
First Trust Capital Management
Illinois
$2.45M +$2.45M +3,475 New
KL
29
KIM LLC
Kansas
$2.45M +$2.45M +3,472 New
Alyeska Investment Group
30
Alyeska Investment Group
Illinois
$2.35M – – –
GCL
31
Glazer Capital LLC
New York
$2.21M +$119K +169 +6%
Nomura Holdings
32
Nomura Holdings
Japan
$2.21M – – –
Balyasny Asset Management
33
Balyasny Asset Management
Illinois
$1.96M – – –
CSS
34
Cubist Systematic Strategies
Connecticut
$1.85M +$1.44M +2,038 +350%
CF
35
Cantor Fitzgerald
New York
$1.67M – – –
DCM
36
Dupont Capital Management
Delaware
$1.47M – – –
FCM
37
Farallon Capital Management
California
$1.47M – – –
CL
38
CSS LLC
Illinois
$999K – – –
Janus Henderson Group
39
Janus Henderson Group
United Kingdom
$991K – – –
MCM
40
Moore Capital Management
New York
$980K – – –
AC
41
Athos Capital
Hong Kong
$876K – – –
CC
42
Centiva Capital
New York
$817K +$14.1K +20 +2%
SSA
43
Schonfeld Strategic Advisors
New York
$797K +$5.64K +8 +0.7%
Ohio Public Employees Retirement System (OPERS)
44
Ohio Public Employees Retirement System (OPERS)
Ohio
$738K +$248K +351 +51%
KCM
45
Kawa Capital Management
Florida
$686K – – –
WAM
46
Wolverine Asset Management
Illinois
$534K -$21.9K -31 -4%
HighTower Advisors
47
HighTower Advisors
Illinois
$515K – – –
HF
48
HRT Financial
New York
$502K – – –
COPPSERS
49
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$491K – – –
TCM
50
Tegean Capital Management
New York
$491K – – –
1
2
3 4

AEON Hedge Fund Activity: Q2 2022 in Review

73 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2022, worth a combined $205M — up 1.3% from $202M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new AEON positions and 6 closed out — a net gain of 2 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was Bank of Montreal, opening a new position worth an estimated $5.51M. The largest seller was Linden Advisors, cutting an estimated $5.51M.

  • 73 institutional investors held AEON Biopharma (AEON) as of Q2 2022, up from 71 in Q1 2022.
  • Funds reported $205M of AEON Biopharma stock for Q2 2022, up 1.3% quarter-over-quarter.
  • 8 funds opened new AEON Biopharma positions in Q2 2022 and 6 closed out, a net change of +2 holders.
  • The largest AEON Biopharma buyer in Q2 2022 was Bank of Montreal, an estimated $5.51M added.
  • The largest AEON Biopharma seller in Q2 2022 was Linden Advisors, an estimated $5.51M sold.

Based on aggregated 13F filings for Q2 2022.